Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups
Novartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO
ASCO for HCPs
Novartis continues to pursue scientific breakthroughs with the ambition to transform lives and renew patients’ hopes for the future.
At Novartis, we’re committed to unraveling the inner workings of cancer. We’re developing new therapies for a range of common and rare cancers, investing in diverse technology platforms and experimenting with combination approaches.
At Novartis, we invest in the most promising frontiers of science, the most exciting innovations in the business of medicine, and the most significant healthcare needs.